Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | MTTP | P55157 | 10/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | APOB | P04114 | 5/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860289 | 0.93 | PPARA (0.43) | PPARAMTTPGAASMN1; SMN2APOB | |
| SCHEMBL5862249 | 0.93 | MTTP (0.45) | PPARAMTTPGAASMN1; SMN2POLB | |
| SCHEMBL5859917 | 0.91 | MAPT (0.48) | PPARASMN1; SMN2 | |
| SCHEMBL5859153 | 0.89 | GAA (0.56) | GAAPOLBNR1H4KDM4ENPC1 | |
| SCHEMBL6095885 | 0.87 | TMPRSS4 (0.50) | PPARASMN1; SMN2AVPR2GPR27 | |
| SCHEMBL5862041 | 0.85 | POLB (0.50) | GAAPOLBKDM4ENPC1RAB9A | |
| SCHEMBL6096112 | 0.84 | PPARA (0.50) | PPARAAVPR2GPR27KDM4E | |
| SCHEMBL5859178 | 0.84 | MAPT (0.48) | SMN1; SMN2 | |
| SCHEMBL5859279 | 0.83 | CYP3A4 (0.48) | GAASMN1; SMN2POLBKDM4ENPC1 | |
| SCHEMBL5859065 | 0.82 | GAA (0.47) | GAASMN1; SMN2POLBKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122543-B2 | Substituted benzoic acid derivatives having NF-κB inhibiting action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| EP-1437339-A1 | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | NFKBIA, NFKB2, IKBKB | PPARA 796/4885MTTP 3284/4885GAA 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.